Accessibility navigation


Sialic acid as a potential biomarker for cardiovascular disease, diabetes and cancer

Cheeseman, J., Kuhnle, G. ORCID: https://orcid.org/0000-0002-8081-8931, Stafford, G., Gardner, R., Spencer, D. and Osborn, H. (2021) Sialic acid as a potential biomarker for cardiovascular disease, diabetes and cancer. Biomarkers in Medicine. ISSN 1752-0363 (In Press)

[img] Text - Accepted Version
· Restricted to Repository staff only
· The Copyright of this document has not been checked yet. This may affect its availability.

864kB

It is advisable to refer to the publisher's version if you intend to cite from this work. See Guidance on citing.

Abstract/Summary

Cardiovascular disease (CVD), diabetes and cancer pose increasing global healthcare burdens. New biomarkers could enable earlier diagnosis of these diseases, leading to more effective treatment and lower associated healthcare burden. Elevated total sialic acid (TSA) concentration in plasma and serum has been positively correlated with cardiovascular conditions diabetes and the development of malignant tumours. This article reviews the use of TSA as a potential biomarker in these disease and makes a comparison with existing markers. Elevated TSA has been shown to be indicative of the pathogenesis of CVD, diabetes and malignant tumours. While not a specific marker for one disease there is promise in utilising TSA as a method for monitoring disease progression and effectiveness of treatment programs.

Item Type:Article
Refereed:Yes
Divisions:Life Sciences > School of Chemistry, Food and Pharmacy > Department of Food and Nutritional Sciences > Human Nutrition Research Group
Life Sciences > School of Chemistry, Food and Pharmacy > School of Pharmacy > Medicinal Chemistry Research Group
ID Code:97615
Publisher:Future Science Group

University Staff: Request a correction | Centaur Editors: Update this record

Page navigation